Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown

Advanced Malignancies Clinical Trials

A listing of Advanced Malignancies medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (299) clinical trials

Safety Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

OVERVIEW: This is a Phase 1, multi-center, open-label, dose-escalation study of TAB001, a humanized monoclonal IgG4 antibody targeting the Programmed Death -1 (PD-1). It is estimated that up to 78 subjects with advanced malignancies will be enrolled in the study. Subjects must have an advanced solid malignancy that is refractory ...


SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

The SYNERGY Registry is an international prospective, observational cohort study of eligible adult and pediatric pts with advanced solid and hematological malignancies, for whom the decision to consider CTE has already been made by their primary providers (PP). Using a proprietary application programming interface (API) linked to existing electronic health ...

Phase N/A

An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

The purpose of this study is to evaluate the safety and tolerability, and determine the maximum tolerated dose of INCB062079 in subjects with advanced hepatocellular carcinoma and other malignancies.


Ceramide NanoLiposome in Patients With Advanced Solid Tumors

This study is a dose escalation study of Ceramide NanoLiposome in patients with advanced solid tumors.


Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies

PRIMARY OBJECTIVES: I. To evaluate the safety of adoptive T cell therapy using ex vivo expanded autologous cluster of differentiation (CD)8+ and CD4+ ROR1 CAR-T cells for patients with advanced ROR1+ hematologic (Cohort A) and epithelial (Cohort B) malignancies. SECONDARY OBJECTIVES: I. To determine duration of in vivo persistence of ...


Dose Escalation Study of mRNA 2416 for Intratumoral Injection to Patients With Advanced Malignancies

This is a first-in-human, Phase 1, open-label, multicenter, dose escalation study designed to determine the safety and tolerability of repeated intratumoral injections of mRNA 2416 in patients with advanced relapsed/refractory solid tumor malignancies or lymphoma. The study will include 2 dosing periods: a Dose Escalation Period followed by an Expansion ...


Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1 FGFR2 FGFR3 FGFR4 RET KIT.

PRIMARY OBJECTIVES: I. To evaluate the response of ponatinib (ponatinib hydrochloride) in patients with fibroblast growth factor receptor (FGFR) altered cancers. SECONDARY OBJECTIVES: I. To assess the safety and tolerability of ponatinib in advanced solid tumors with genomic FGFR alterations. II. To assess progression free survival (PFS) and overall survival ...


Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing

This study supports the collection of tumor specimens for CLIA-certified genomic testing and research testing in parallel. CLIA-certified tests have established measurements of accuracy and precision which allow for return of results. This study does not involve treatment, only testing, which could be used to meet eligibility criteria in other ...

Phase N/A

A Study of Coti-2 for the Treatment of Advanced or Recurrent Gynecologic Malignancies

This is a single arm, single center, open-label, Phase 1, first time in human study of COTI-2 in patients with recurrent ovarian,fallopian tube,primary peritoneal cancer, endometrial, cervical or head and neck cancer. COTI-2 will be self-administered as a single agent, orally, once daily for 5 days followed by 2 treatment-free ...


A Phase I Study of DFP-13318 in Patients With Advanced Solid Tumors

DFP-11318 is an investigational drug product that has demonstrated reasonable antitumor activity in preclinical colorectal, gastric and lung tumor models in animals. This is a first in human trial to determine the maximum, safest dose of DFP-11318 IV that can be administered to patients either once every 3 weeks or ...